Press Releases

PTC Therapeutics, Inc. is committed to serving the interests of all our stakeholders.
Danya
Living with
Duchenne Muscular Dystrophy,
Ukraine
DANYA - Duchenne Muscular Dysthropy- Ukraine

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.


Date Title and Summary View
May 31, 2022 FDA Approves Label Extension for Evrysdi® for Infants with Spinal Muscular Atrophy Under 2 Months Old
- Evrysdi is the first and only at-home administered treatment for patients living with SMA - - Evrysdi has proven efficacy in babies, children and adults with more than 5,000 patients treated to date - SOUTH PLAINFIELD, N.J. , May 31, 2022 /PRNewswire/ -- PTC Therapeutics, Inc.
May 20, 2022 PTC Therapeutics Receives Positive CHMP Opinion for Upstaza™ for the Treatment of AADC Deficiency
– First ever gene therapy directly administered into the brain – – Recommended for regulatory approval by EMA – – Results demonstrated sustained improvements in motor and cognitive function – – Conference call scheduled for Monday, May 23 , at 8 a.m. ET – SOUTH PLAINFIELD, N.J.
May 03, 2022 PTC Therapeutics Provides a Corporate Update and Reports First Quarter Financial Results
- $149 million total revenue representing impressive 26% year-over-year growth – - Initiation of PIVOT-HD Phase 2 trial of PTC518 in Huntington's disease – - CHMP opinion on AADC gene therapy expected in May; ready to execute on potential launch – SOUTH PLAINFIELD, N.J.
Apr 29, 2022 PTC Therapeutics to Participate at Upcoming Investor Conferences
SOUTH PLAINFIELD, N.J. , April 29, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the following conferences: Bank of America Securities 2002 Healthcare Conference Tuesday, May 10 at 5:20 p.m.
Apr 19, 2022 PTC Therapeutics to Host Conference Call to Discuss First Quarter 2022 Financial Results
SOUTH PLAINFIELD, N.J. , April 19, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its first quarter 2022 financial results and provide an update on the company's business and outlook on Tuesday, May 3 , at
Apr 14, 2022 PTC Therapeutics Provides Update on EMA Regulatory Review Timeline For Its AADC Deficiency Gene Therapy Program
- CHMP Opinion Now Expected May 2022 - SOUTH PLAINFIELD, N.J. , April 14, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that it has completed the Scientific Advisory Group and Oral Explanation meetings for its gene therapy treatment for AADC deficiency (PTC-AADC) with
Apr 08, 2022 PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SOUTH PLAINFIELD, N.J. , April 8, 2022 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) today announced that on April 8, 2022 , the company approved non-statutory stock options to purchase an aggregate of 86,130 shares of its common stock and 33,125 restricted stock units ("RSUs"), each
Mar 30, 2022 PTC Therapeutics Announces Initiation of PIVOT-HD Phase 2 Clinical Trial to Evaluate PTC518 in Patients with Huntington's Disease
SOUTH PLAINFIELD, N.J. , March 30, 2022  /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the initiation of the PIVOT-HD Phase 2 clinical trial evaluating PTC518 in people with Huntington's disease (HD). PIVOT-HD is a global trial starting in the United States .
Mar 11, 2022 PTC Therapeutics to Present New Data at the 2022 Muscular Dystrophy Association Clinical & Scientific Conference
SOUTH PLAINFIELD, N.J. , March 11, 2022 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present three posters outlining data for EMFLAZA™ (deflazacort) in Duchenne muscular dystrophy (DMD) at the Muscular Dystrophy Association (MDA) Clinical & Scientific
Feb 23, 2022 PTC Therapeutics to Participate at Upcoming Investor Conferences
SOUTH PLAINFIELD, N.J. , Feb. 23, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the following conferences:     Cowen Virtual 42nd Annual Health Care Conference Monday, March 7 at 1:30 p.m.